Targeting tuberculosis using structure-guided fragment-based drug design

Drug Discovery Today

Volumn 22, Issue 3, 2017, Pages 546-554

  Mendes, Vitor ^a   Blundell, Tom L ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL ENZYME; COENZYME A; CYTOCHROME P450; CYTOCHROME P450 121; DEHYDROQUINOLASE; NEW DRUG; PHOSPHOTRANSFERASE; THYMIDYLATE KINASE; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; ETHIONAMIDE; ETHR PROTEIN, MYCOBACTERIUM TUBERCULOSIS; REPRESSOR PROTEIN;

ANTIBACTERIAL ACTIVITY; ANTIMYCOBACTERIAL ACTIVITY; BACTERIAL CELL WALL; DRUG DESIGN; DRUG DEVELOPMENT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; ENZYME SYNTHESIS; FRAGMENT BASED DRUG DISCOVERY; HUMAN; NONHUMAN; REVIEW; TUBERCULOSIS; ANIMAL; CELL WALL; METABOLISM; MYCOBACTERIUM TUBERCULOSIS; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CELL WALL; COENZYME A; DRUG DESIGN; ETHIONAMIDE; HUMANS; MYCOBACTERIUM TUBERCULOSIS; REPRESSOR PROTEINS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBERCULOSIS;

EID: 85006048223     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2016.10.003     Document Type: Review

References (65)

1. 1 Wallis, R.S., et al. Tuberculosis – advances in development of new drugs, treatment regimens, host-directed therapies, and biomarkers. Lancet Infect. Dis. 16 (2016), e34–e46.
2. 2 Koul, A., et al. The challenge of new drug discovery for tuberculosis. Nature 469 (2011), 483–490.
3. 3 Payne, D.J., et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat. Rev. Drug Discov. 6 (2007), 29–40.
4. 4 Zumla, A., et al. Advances in the development of new tuberculosis drugs and treatment regimens. Nat. Rev. Drug Discov. 12 (2013), 388–404.
5. 5 Prideaux, B., et al. The association between sterilizing activity and drug distribution into tuberculosis lesions. Nat. Med. 21 (2015), 1223–1227.
6. 6 Blundell, T.L., et al. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 1 (2002), 45–54.
7. 7 Mashalidis, E.H., et al. A three-stage biophysical screening cascade for fragment-based drug discovery. Nat. Protoc. 8 (2013), 2309–2324.
8. 8 Erlanson, D.A., et al. Twenty years on: the impact of fragments on drug discovery. Nat. Rev. Drug Discov. 15 (2016), 605–619.
9. 9 Scott, D.E., et al. Fragment-based approaches in drug discovery and chemical biology. Biochemistry 51 (2012), 4990–5003.
10. 10 Murray, C.W., Rees, D.C., The rise of fragment-based drug discovery. Nat. Chem. 1 (2009), 187–192.
11. 11 Niesen, F.H., et al. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat. Protoc. 2 (2007), 2212–2221.
12. 12 Vivoli, M., et al. Determination of protein–ligand interactions using differential scanning fluorimetry. J. Vis. Exp., 91, 2014, 51809.
13. 13 Dalvit, C., et al. WaterLOGSY as a method for primary NMR screening: practical aspects and range of applicability. J. Biomol. NMR 21 (2001), 349–359.
14. 14 Klages, J., et al. NMR-based screening: a powerful tool in fragment-based drug discovery. Analyst 132 (2007), 693–705.
15. 15 Mayer, M., Meyer, B., Characterization of ligand binding by saturation transfer difference NMR spectroscopy. Angew. Chem. Int. Ed. Engl. 38 (1999), 1784–1788.
16. 16 Hajduk, P.J., et al. One-dimensional relaxation- and diffusion-edited NMR methods for screening compounds that bind to macromolecules. J. Am. Chem. Soc. 119 (1997), 12257–12261.
17. 17 Navratilova, I., Hopkins, A.L., Fragment screening by surface plasmon resonance. ACS Med. Chem. Lett. 1 (2010), 44–48.
18. 18 Wartchow, C.A., et al. Biosensor-based small molecule fragment screening with biolayer interferometry. J. Comput. Aided Mol. Des. 25 (2011), 669–676.
19. 19 Maple, H.J., et al. Automated protein–ligand interaction screening by mass spectrometry. J. Med. Chem. 55 (2012), 837–851.
20. 20 Linke, P., et al. An automated microscale thermophoresis screening approach for fragment-based lead discovery. J. Biomol. Screen. 21 (2016), 414–421.
21. 21 Schiebel, J., et al. One question, multiple answers: biochemical and biophysical screening methods retrieve deviating fragment hit lists. ChemMedChem 10 (2015), 1511–1521.
22. 22 Lawson, A.D., Antibody-enabled small-molecule drug discovery. Nat. Rev. Drug Discov. 11 (2012), 519–525.
23. 23 Renaud, J.P., et al. Biophysics in drug discovery: impact, challenges and opportunities. Nat. Rev. Drug Discov. 15 (2016), 679–698.
24. 24 Hall, D.R., et al. Lessons from hot spot analysis for fragment-based drug discovery. Trends Pharmacol. Sci. 36 (2015), 724–736.
25. 25 Radoux, C.J., et al. Identifying interactions that determine fragment binding at protein hotspots. J. Med. Chem. 59 (2016), 4314–4325.
26. 26 Leonardi, R., et al. Coenzyme A: back in action. Prog. Lipid Res. 44 (2005), 125–153.
27. 27 Silvestre, H.L., et al. Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 12984–12989.
28. 28 Hung, A.W., et al. Application of fragment growing and fragment linking to the discovery of inhibitors of Mycobacterium tuberculosis pantothenate synthetase. Angew. Chem. Int. Ed. Engl. 48 (2009), 8452–8456.
29. 29 Hung, A.W., et al. Optimization of inhibitors of Mycobacterium tuberculosis pantothenate synthetase based on group efficiency analysis. ChemMedChem 11 (2016), 38–42.
30. 30 Jankute, M., et al. Assembly of the mycobacterial cell wall. Annu. Rev. Microbiol. 69 (2015), 405–423.
31. 31 Puech, V., et al. Evidence for a partial redundancy of the fibronectin-binding proteins for the transfer of mycoloyl residues onto the cell wall arabinogalactan termini of Mycobacterium tuberculosis. Mol. Microbiol. 44 (2002), 1109–1122.
32. 32 Belisle, J.T., et al. Role of the major antigen of Mycobacterium tuberculosis in cell wall biogenesis. Science 276 (1997), 1420–1422.
33. 33 Jackson, M., et al. Inactivation of the antigen 85C gene profoundly affects the mycolate content and alters the permeability of the Mycobacterium tuberculosis cell envelope. Mol. Microbiol. 31 (1999), 1573–1587.
34. 34 Favrot, L., et al. Mechanism of inhibition of Mycobacterium tuberculosis antigen 85 by ebselen. Nat. Commun., 4, 2013, 2748.
35. 35 Scheich, C., et al. Novel small molecule inhibitors of MDR Mycobacterium tuberculosis by NMR fragment screening of antigen 85C. J. Med. Chem. 53 (2010), 8362–8367.
36. 36 Bhatt, A., et al. Conditional depletion of KasA, a key enzyme of mycolic acid biosynthesis, leads to mycobacterial cell lysis. J. Bacteriol. 187 (2005), 7596–7606.
37. 37 Wang, J., et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 441 (2006), 358–361.
38. 38 Price, A.C., et al. Inhibition of beta-ketoacyl-acyl carrier protein synthases by thiolactomycin and cerulenin. Structure and mechanism. J. Biol. Chem. 276 (2001), 6551–6559.
39. 39 Kapilashrami, K., et al. Thiolactomycin-based beta-ketoacyl-AcpM synthase A (KasA) inhibitors: fragment-based inhibitor discovery using transient one-dimensional nuclear overhauser effect NMR spectroscopy. J. Biol. Chem. 288 (2013), 6045–6052.
40. 40 Bernardes-Genisson, V., et al. Isoniazid: an update on the multiple mechanisms for a singular action. Curr. Med. Chem. 20 (2013), 4370–4385.
41. 41 Phelan, J., et al. Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance. BMC Med., 14, 2016, 31.
42. 42 Encinas, L., et al. Encoded library technology as a source of hits for the discovery and lead optimization of a potent and selective class of bactericidal direct inhibitors of Mycobacterium tuberculosis InhA. J. Med. Chem. 57 (2014), 1276–1288.
43. 43 Manjunatha, U.H., et al. Direct inhibitors of InhA are active against Mycobacterium tuberculosis. Sci. Transl. Med., 7, 2015, 269ra263.
44. 44 Sink, R., et al. Design, synthesis, and evaluation of new thiadiazole-based direct inhibitors of enoyl acyl carrier protein reductase (InhA) for the treatment of tuberculosis. J. Med. Chem. 58 (2015), 613–624.
45. 45 Wang, F., et al. Mechanism of thioamide drug action against tuberculosis and leprosy. J. Exp. Med. 204 (2007), 73–78.
46. 46 Willand, N., et al. Synthetic EthR inhibitors boost antituberculous activity of ethionamide. Nat. Med. 15 (2009), 537–544.
47. 47 Nikiforov, P.O., et al. A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. Org. Biomol. Chem. 14 (2016), 2318–2326.
48. 48 Villemagne, B., et al. Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. J. Med. Chem. 57 (2014), 4876–4888.
49. 49 Surade, S., et al. A structure-guided fragment-based approach for the discovery of allosteric inhibitors targeting the lipophilic binding site of transcription factor EthR. Biochem. J. 458 (2014), 387–394.
50. 50 Frenois, F., et al. Structure of EthR in a ligand bound conformation reveals therapeutic perspectives against tuberculosis. Mol. Cell 16 (2004), 301–307.
51. 51 Kumar, A., et al. New molecular scaffolds for the design of Mycobacterium tuberculosis type II dehydroquinase inhibitors identified using ligand and receptor based virtual screening. J. Mol. Model. 16 (2010), 693–712.
52. 52 Tran, A.T., et al. Elucidation of Mycobacterium tuberculosis type II dehydroquinase inhibitors using a fragment elaboration strategy. ChemMedChem 7 (2012), 1031–1043.
53. 53 Van Calenbergh, S., et al. Drug design and identification of potent leads against mycobacterium tuberculosis thymidine monophosphate kinase. Curr. Top. Med. Chem. 12 (2012), 694–705.
54. 54 Naik, M., et al. Structure guided lead generation for M. tuberculosis thymidylate kinase (Mtb TMK): discovery of 3-cyanopyridone and 1,6-naphthyridin-2-one as potent inhibitors. J. Med. Chem. 58 (2015), 753–766.
55. 55 Cole, S.T., et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature 393 (1998), 537–544.
56. 56 McLean, K.J., et al. The preponderance of P450s in the Mycobacterium tuberculosis genome. Trends Microbiol. 14 (2006), 220–228.
57. 57 McLean, K.J., et al. Characterization of active site structure in CYP121. A cytochrome P450 essential for viability of Mycobacterium tuberculosis H37Rv. J. Biol. Chem. 283 (2008), 33406–33416.
58. 58 Seward, H.E., et al. Crystal structure of the Mycobacterium tuberculosis P450 CYP121-fluconazole complex reveals new azole drug-P450 binding mode. J. Biol. Chem. 281 (2006), 39437–39443.
59. 59 McLean, K.J., et al. Azole antifungals are potent inhibitors of cytochrome P450 mono-oxygenases and bacterial growth in mycobacteria and streptomycetes. Microbiology 148 (2002), 2937–2949.
60. 60 Kavanagh, M.E., et al. Fragment-based approaches to the development of Mycobacterium tuberculosis CYP121 inhibitors. J. Med. Chem. 59 (2016), 3272–3302.
61. 61 Hudson, S.A., et al. Overcoming the limitations of fragment merging: rescuing a strained merged fragment series targeting Mycobacterium tuberculosis CYP121. ChemMedChem 8 (2013), 1451–1456.
62. 62 Hudson, S.A., et al. Application of fragment screening and merging to the discovery of inhibitors of the Mycobacterium tuberculosis cytochrome P450 CYP121. Angew. Chem. Int. Ed. Engl. 51 (2012), 9311–9316.
63. 63 Davis, H.J., et al. Spirooxindoles as novel 3D-fragment scaffolds: synthesis and screening against CYP121 from M. tuberculosis. Bioorg. Med. Chem. Lett. 26 (2016), 3735–3740.
64. 64 Danilchanka, O., et al. Role of porins for uptake of antibiotics by Mycobacterium smegmatis. Antimicrob. Agents Chemother. 52 (2008), 3127–3134.
65. 65 Gopal, P., Dick, T., Reactive dirty fragments: implications for tuberculosis drug discovery. Curr. Opin. Microbiol. 21 (2014), 7–12.